Cystic fibrosis papers of the year 2017

被引：2

作者：

Doull, Iolo ^{[1
,2
]}

机构：

[1] Childrens Hosp Wales, Dept Paediat Resp Med, Cardiff CF14 4XN, S Glam, Wales

[2] Childrens Hosp Wales, Paediat Cyst Fibrosis Ctr, Cardiff CF14 4XN, S Glam, Wales

来源：

PAEDIATRIC RESPIRATORY REVIEWS | 2018年 / 27卷

关键词：

Cystic fibrosis; Ivacaftor; Lumacaftor; Tezacaftor; Doxycycline; MRSA; RESISTANT STAPHYLOCOCCUS-AUREUS; PHE508DEL CFTR MUTATION; AGED; 6-11; YEARS; TEZACAFTOR-IVACAFTOR; LUNG-FUNCTION; LUMACAFTOR/IVACAFTOR; EFFICACY; F508DEL-CFTR; COMBINATION; PHASE-3;

D O I：

10.1016/j.prrv.2018.03.001

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

The number of published articles on Cystic Fibrosis (CF) continues to increase year on year. The evidence base for small molecule therapies in CF has continued to expand, with evidence for lumacaftor/ivacaftor in younger patients and longer-term evidence in adults, and pivotal studies on tezacaftor/ivacaftor. There were reports on emerging CFTR mutation agnostic therapies, and new evidence for long standing therapies. (C) 2018 Elsevier Ltd. All rights reserved.

引用

页码：2 / 5

页数：4

共 50 条

[31] Cystic fibrosis year in review 2023 [J].

Swetland, David V. ;

Savant, Adrienne P. .

PEDIATRIC PULMONOLOGY, 2024, 59 (12) :3106-3116

[32] A Review on the Use of Cystic Fibrosis Transmembrane Conductance Regulator Gene Modulators in Pediatric Patients [J].

Bitonti, Michael ;

Fritts, Laura ;

So, Tsz-Yin .

JOURNAL OF PEDIATRIC HEALTH CARE, 2019, 33 (03) :356-364

[33] Patients with cystic fibrosis and advanced lung disease benefit from lumacaftor/ivacaftor treatment [J].

Ejiofor, Linnea Chika Kristensen ;

Mathiesen, Inger Hee Mabuza ;

Jensen-Fangel, Soren ;

Olesen, Hanne Vebert ;

Skov, Marianne ;

Philipsen, Lue Katrine Drasbaek ;

Pedersen, Camilla Lundgren ;

Pressler, Tacjana .

PEDIATRIC PULMONOLOGY, 2020, 55 (12) :3364-3370

[34] Allergic Bronchopulmonary Aspergillosis (ABPA) in the Era of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators [J].

Chatterjee, Paulami ;

Moss, Carson Tyler ;

Omar, Sarah ;

Dhillon, Ekroop ;

Borges, Carlos Daniel Hernandez ;

Tang, Alan C. ;

Stevens, David A. ;

Hsu, Joe L. .

JOURNAL OF FUNGI, 2024, 10 (09)

[35] Tezacaftor for the treatment of cystic fibrosis [J].

Sala, Marc A. ;

Jain, Manu .

EXPERT REVIEW OF RESPIRATORY MEDICINE, 2018, 12 (09) :725-732

[36] Precision medicine in cystic fibrosis [J].

Andrade, Arlette ;

Ester Pizarro, Maria .

REVISTA MEDICA CLINICA LAS CONDES, 2022, 33 (01) :44-50

[37] Drug treatment of cystic fibrosis [J].

Bruorton, Matthew ;

Goddard, Thomas .

AUSTRALIAN PRESCRIBER, 2022, 45 (05) :171-175

[38] Triple combination cystic fibrosis transmembrane conductance regulator modulator therapy in the real world - opportunities and challenges [J].

Barry, Peter J. ;

Taylor-Cousar, Jennifer L. .

CURRENT OPINION IN PULMONARY MEDICINE, 2021, 27 (06) :554-566

[39] Compassionate Use of Lumacaftor/Ivacaftor in Cystic Fibrosis: Spanish Experience [J].

Diab-Caceres, Layla ;

Maria Giron-Moreno, Rosa ;

Teresa Pastor-Sanz, Maria ;

Quintana-Gallego, Esther ;

Delgado-Pecellin, Isabel ;

Blanco-Aparicio, Marina ;

Maiz, Luis ;

Maria Garcia-Clemente, Marta ;

Luna-Paredes, Carmen ;

Mondejar-Lopez, Pedro ;

Ruiz-de-Valbuena, Marta ;

Fernandez, Ofelia ;

Barrio, Maribel ;

Gonzalez, Maribel ;

Lopez-Neyra, Alejandro ;

Cols-i-Roig, Maria ;

Palou-Rotger, Alexandre ;

Javier Gomez-de-Terreros-Caro, Francisco .

ARCHIVOS DE BRONCONEUMOLOGIA, 2018, 54 (12) :614-618

[40] CFTR-function and ventilation inhomogeneity in individuals with cystic fibrosis [J].

Bernasconi, Nadine ;

Kieninger, Elisabeth ;

Shaw, Michelle ;

Kurz, Johanna ;

Moeller, Alexander ;

Ratjen, Felix ;

Rochat, Isabelle ;

Stanojevic, Sanja ;

Singer, Florian .

JOURNAL OF CYSTIC FIBROSIS, 2021, 20 (04) :641-647

← 1 2 3 4 5 →